Psoriasis improvement after bariatric surgery

Romero-Talamás, Héctor; Aminian, Ali; Corcelles, Ricard; Fernandez, Anthony P.; Schauer, Philip R.; Brethauer, Stacy A.

doi:10.1016/j.soard.2014.03.025

Cited by 45 publications

(34 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An improvement or disease remission is noted in 40-60% of patients, based on recognized scores used for measuring the activity of psoriasis. Consequently, it is possible to reduce the dosage of systemic therapy used thus far or terminate treatment altogether in over 20% of patients [65,66]. Dyslipidemia koreluje ze zwiększoną śmiertelnością z powodu MI i udaru [58].…”

Section: Obesitymentioning

confidence: 99%

“…Obserwuje się poprawę lub remisję u 40-60% pacjentów, stwierdzone na podstawie uznanych skal oceny aktywności łuszczy-cy. Ponadto możliwe jest zmniejszenie dawkowania dotychczas stosowanej terapii ogólnej lub jej całko-wite zakończenie u ponad 20% pacjentów [65,66]. Jest to wynikiem m.in.…”

Section: Obesityunclassified

“…Jest to wynikiem m.in. utraty masy ciała, zwiększo-nego wydzielania peptydu glukagonopodobnego 1, zmniejszenia motoryki przewodu pokarmowego i efektu przeciwzapalnego [5,65,66].…”

Section: Obesityunclassified

“…The above outcomes result from the body weight loss itself, but also from an increased production of glucagon-like peptide-1, reduced gastrointestinal motility and antiinflammatory effect [5,65,66].…”

Section: Obesitymentioning

confidence: 99%

See 3 more Smart Citations

The role of lipids in psoriasis

Baran¹,

Kiluk²,

Myśliwiec³

et al. 2017

View full text Add to dashboard Cite

Psoriasis, affecting 2-4% of the world's population, is a chronic recurrent inflammatory skin disease. Its multifactorial aetiopathogenesis consists of, for example, abnormal epidermal proliferation, immune disturbances, and genetic, psychosomatic, environmental and hormonal factors. Psoriasis is also considered to be a systemic disorder closely associated with cardiovascular diseases, atherosclerosis, diabetes mellitus, obesity or metabolic syndrome. Lipids have a variety of biological functions. They participate not only in energy storage and expenditure or the formation of cell membranes, but also in inflammatory and metabolic signalling pathways. Disturbances in their homeostasis lead to the development of immunometabolic disorders, including psoriasis. Based on the available literature, this article presents selected molecular and clinical aspects involved in the multidirectional effect of lipids on psoriasis.streszczenie Łuszczyca, która występuje u 2-4% populacji na świecie, jest przewlekłą i nawrotową chorobą zapalną skóry. Na jej wieloczynnikową etiopatogenezę składają się m.in. nieprawidłowa proliferacja naskórka, zaburzenia immunologiczne, czynniki genetyczne, psychosomatyczne, środowiskowe i hormonalne. Łuszczyca jest również uznawana za schorzenie ogólnoustrojowe, związane z chorobami układu sercowo--naczyniowego, miażdżycą, cukrzycą, otyłością i zespołem metabolicznym. Lipidy pełnią wiele biologicznych funkcji, biorą udział nie tylko w magazynowaniu i wydatkowaniu energii, tworzeniu błon komórko-wych, lecz także w zapalnych i metabolicznych szlakach sygnałowych. Zaburzenia ich homeostazy powodują rozwój schorzeń immunometabolicznych, w tym łuszczycy. W niniejszej pracy przedstawiono na podstawie dostępnego piśmiennictwa wybrane aspekty molekularne i kliniczne wielokierunkowego wpływu lipidów na łuszczycę.

show abstract

Section: Obesitymentioning

confidence: 99%

Section: Obesityunclassified

“…Jest to wynikiem m.in. utraty masy ciała, zwiększo-nego wydzielania peptydu glukagonopodobnego 1, zmniejszenia motoryki przewodu pokarmowego i efektu przeciwzapalnego [5,65,66].…”

Section: Obesityunclassified

Section: Obesitymentioning

confidence: 99%

See 2 more Smart Citations

The role of lipids in psoriasis

Baran¹,

Kiluk²,

Myśliwiec³

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Sparks et al [24] reported a decrease in rheumatoid arthritis disease activity enabling lower medication use following SG. Romero-Talamás et al [25] observed a decrease in psoriasis in 40% of patients following RYGBP and found that the remission correlated with the extent of excess weight loss. Yildiz [26] reported remission of psoriasis already 1 month after SG in 2 patients.…”

Section: Bs and Inflammationmentioning

confidence: 99%

Does Gastric Surgery (Such as Bariatric Surgery) Impact the Risk of Intestinal Inflammation?

2016

View full text Add to dashboard Cite

Background: The prevalence of morbid obesity and inflammatory bowel disease (IBD) is on the rise in association with a Western lifestyle. Both conditions are characterized by chronic inflammation. Bariatric surgery (BS) is a recommended and widely used approach to address severe obesity and its related comorbidities. Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy (SG) are the most frequently performed procedures worldwide. Evidence is scarce on outcomes of BS in IBD patients. Summary: Systemic and adipose-tissue inflammation seems to decrease following BS. Different studies observed decreased serum levels of inflammatory markers (CRP, IL-6, MCP-1, and TNF-α) along with a reduction of insulin resistance both after RYGBP and SG. Several authors documented postbariatric improvement of concomitant chronic inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, gout, and psoriasis). There are only few retrospective case series on outcomes of BS in IBD patients. These studies reported safety and feasibility of BS and improvement in IBD status, manifested by prolonged disease remission and decreased use of pharmacotherapy. Weight loss outcomes were excellent and similar to those of non-IBD patients. The preferred surgical approach for morbidly obese IBD patients is SG in order to avoid potential drawbacks of RYGBP, such as malabsorption, intestinal manipulation, and augmentation of technical difficulties for future IBD surgery. Seven cases of newly diagnosed IBD after BS have been reported, which are more likely to result from postoperative intestinal microbial dysbiosis than from directly induced inflammation. Key Messages: This review summarizes the outcomes of BS in IBD patients. SG is the preferable technique for morbidly obese IBD patients, who have potentially a double benefit from BS: weight loss and IBD remission. Further research is necessary to clarify the common pathophysiology of chronic inflammation in morbid obesity and in IBD. Postbariatric changes in gut microbiota should also be assessed to understand whether they promote IBD development or not.

show abstract